A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
New devices are coming, but the real advances will involve combinations.
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Novel approaches including gene editing are creeping towards approval.